Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive giant prolactinoma. Here, we report a case of invasive giant prolactinoma in a 52-year-old Saudi male with dramatic response to cabergoline treatment clinically, biochemically, and radiologically
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. The...
Prolactinomas are the most common hormone-secreting pituitary tumours and cause infertility and gona...
The term 'giant prolactinoma' can be used for tumours larger than 4 cm in diameter and/or with massi...
Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes...
Numerous studies showed an association between prolactin levels and body weight, with increased prev...
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction...
Although advances in endocrinologic and neuroradiologic research allow easier recognition of pituita...
Prolactinomas are the most common pituitary tumors but rarely seen in adolescent males. There is no ...
Background. Prolactinomas invading the skull base are rare, and could easily be confused with skull ...
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in ...
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Different weekly doses (400 to 3,000 micrograms) of the new, long-acting dopamine agonist Cabergolin...
In 1970 a 20 year old woman presented with a pituitary chromophobe adenoma for which she underwent t...
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. The...
Prolactinomas are the most common hormone-secreting pituitary tumours and cause infertility and gona...
The term 'giant prolactinoma' can be used for tumours larger than 4 cm in diameter and/or with massi...
Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes...
Numerous studies showed an association between prolactin levels and body weight, with increased prev...
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction...
Although advances in endocrinologic and neuroradiologic research allow easier recognition of pituita...
Prolactinomas are the most common pituitary tumors but rarely seen in adolescent males. There is no ...
Background. Prolactinomas invading the skull base are rare, and could easily be confused with skull ...
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in ...
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Different weekly doses (400 to 3,000 micrograms) of the new, long-acting dopamine agonist Cabergolin...
In 1970 a 20 year old woman presented with a pituitary chromophobe adenoma for which she underwent t...
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patie...
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. The...
Prolactinomas are the most common hormone-secreting pituitary tumours and cause infertility and gona...